Semnur Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Apr 1, 2024 and accepted by EDGAR at Apr 1, 2024, 16:41 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $36.9k | us-gaap:InterestExpense |
| Net income | 12 months2023-01-01 to 2023-12-31 | $632.5k | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | −$632.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $40.5m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-12-31 | $204.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $209.4k | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $50.7m | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $5.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $8.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-12-31 | −$8.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-028809. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.